Ashu Dogra, Kaushik Rana, Devanshi Gosai
Background: Dengue has been emerging as rapidly spreading and dreaded mosquito borne disease caused by the bite of Aedes Aegypti Mosquito. Clinical features are variable and presents with Dengue fever or Dengue Hemorrhagic fever or more severe Dengue shock syndrome. Thrombocytopenia is presenting feature in in all Dengue cases and some often presents with bleeding. Platelet transfusions are given in patients with haemorrhagic symptoms.
Present study thus aims to study the effectiveness of platelet transfusion in management of Dengue patients with Dengue haemorrhagic fever and Dengue shock syndrome.
Results: In present study, a total of 20 patients were diagnosed as dengue confirmed cases by serological testing methods. Out of 20, 12 (60%) patients had dengue fever with platelet count in range of 50,000-80,000 per μl. Two patients with Dengue fever had Petechial spots with platelet count in range of 50,000 per μl and were given prophylactic Single Donor Platelet Transfusions. Eight patients (40%) presented with Dengue Haemorrhagic fever and platelet count of < 20,000 per μl. These patients were given single donor platelet transfusions. Six patients responded good with CCI of > 30,000 per μl and 2 patients recorded as non-responders.
Conclusion: This study suggests that 25% Platelet transfusions are inappropriate. Platelet transfusions are more effective when it is given to patients with platelet count <20,000 per μl. Platelet transfusion should be given based on platelet count and hemorrhagic manifestations, as this decreases hospitalization of patients and complications of dengue.
Published Date: 2021-03-29; Received Date: 2021-03-08